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The EUTOS Long-Term Survival score was tested in 350 childrenwith chronic myeloid leukemia in first chronic phase treated withimatinib and registered in the International Registry for Childhood
Chronic Myeloid Leukemia. With a median follow up of 3 years (range,
1 month to 6 years) progression and/or death (whichever came first)
occurred in 23 patients.  For the entire cohort of patients the 5-year pro-
gression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year
survival accounting for chronic myeloid leukemia deaths was 97% (95%
CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermedi-
ate (n=68) and high (n=42) risk groups by the EUTOS Long-Term
Survival score, events (progression and/or death) occurred in 6.0%, 8.8%
and 26.2%, respectively. Estimates of the 5-year progression-free sur-
vival rates according to these three risk groups were 96% (95% CI: 92%-
98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respec-
tively. Differences in progression-free survival according to these risk
groups were highly significant (P<0.0001, overall). The EUTOS Long-
Term Survival score showed better differentiation of progression-free
survival than the Sokal (<45 years), Euro  and EUTOS scores in children
and adolescents with chronic myeloid leukemia and should be consid-
ered in therapeutic  algorithms. (Trial registered at: www.clinicaltrials.gov
NCT01281735)
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ABSTRACT
Introduction 
Prognostic scores such as the Sokal score, the Euro score and the EUTOS score
based on clinical and biological features at diagnosis have proven their usefulness
in predicting the outcome of adults receiving defined treatment for chronic
myeloid leukemia (CML).1-3 While the Sokal score for patients less than 45 years
old and the Euro score were defined in cohorts of patients
including children, the usefulness of these prognostic
scores has not been formally established in the pediatric
population.4 Limited data are available regarding the utili-
ty of the EUTOS score in the pediatric population.5
Recently, a new EUTOS score, the EUTOS Long-Term
Survival (ELTS) score was validated in the adult popula-
tion and showed better discrimination of the probability
of dying of CML than had previous prognostic scores.6
The International Registry for Chronic Myeloid Leukemia
in children and adolescents (I-CML-Ped Study registered
at www.clinicaltrials.gov as NCT01281735) gave us the
opportunity to compare risk group allocations and out-
come between these prognostic scores in the pediatric
population.
Methods
The I-CML-Ped Study was established to assess the epidemiol-
ogy, management and outcome of CML in the pediatric popula-
tion. Newly diagnosed children and adolescents less than 18 years
old with Philadelphia chromosome-positive CML in chronic or
advanced phase diagnosed later than January 2000 were eligible
for this study. The calculations for the Sokal (for patients less than
45 years old), Euro, EUTOS and ELTS scores were performed
using mathematical equations including the following parameters:
sex, spleen size, hematocrit, platelets and blasts in blood for the
Sokal score; age, spleen size, platelets, blasts, basophils and
eosinophils in blood for the Euro score; spleen size and basophils
in blood for the EUTOS score; and age, spleen size, platelets and
blasts in blood for the ELTS score, as previously reported.2-4,6 On
the basis of the calculated scores, the children were categorized
into low risk, intermediate risk or high risk groups for the Sokal
(for patients less than 45 years), Euro and EUTOS scores and into
low risk or high risk for the ELTS score. The phase of the disease
was determined according to the European leukemiaNet (ELN)
recommendations as previously reported.7 The study protocol was
approved by the institutional review committee of the university
hospital of Poitiers (France). Written informed consent was
obtained from the children and/or their guardians. For analyses of
progression-free survival, events of interest included progression
to accelerated phase or blast crisis and death, irrespective of cause,
whichever came first.8 For analysis of survival, the event of interest
was death from CML disease, deaths from other causes being con-
sidered as competing events, as initially designed in the ELTS score
model. The follow up of patients was not censored at the time of
switching to other drugs or allogeneic hematopoietic stem cell
transplantation (HSCT). Estimates of progression-free survival
were calculated using the Kaplan-Meier method and comparisons
were performed using the log-rank test. For the estimation of
cause-specific death in a competing model, the Gray test was used
for comparison.9 The level of statistical significance was 0.05.  
Results 
Between January 2011 and June 2016, 350 patients with
CML in chronic phase at diagnosis  treated with standard
dose (260 to 300 mg/m2 daily) imatinib front line were reg-
istered from 13 countries. The patients’ median age at
diagnosis of CML was 12.2 years (range, 8 months to 18
Pertinence of ELTS score in children with CML
haematologica | 2017; 102(10) 1705
Table 1. Probabilities of progression-free survival and survival accounting for competing events in children with chronic myeloid leukemia treated
with imatinib.
Prognostic score Number of Progression 5-year PFS P CML Competing 5-year survival P
cases n (%) or death estimate deaths events estimate 
(% risk group) (95% CI) (% risk group) (% risk group) (95% CI)
accounting
for CML deaths
Sokal  young score
Low risk 54 (18%) 3 (5.5%) 93% (81-98) 0 2 (3.7%) 100%
Intermediate risk 118 (38%) 6 (5%) 94% (87-97) P=0.279 2 (1.7%) 2 (1.7%) 97% (92-100) P=0.576
High risk 137 (44%) 14 (10.2%) 87% (79-92) 3 (2.2%) 3 (2.2%) 96% (89-100)
Missing 41
Euro score
Low risk 165 (55%) 9 (5.5%) 94% (88-97) 2 (1.2%) 3 (1.8%) 98% (94-100)
Intermediate risk 103 (34%) 9 (8.7%) 89% (79-94) P=0.211 1 (1%) 4 (3.9%) 99% (93-100) P=0.182
High risk 35 (12%) 5 (14.3%) 81% (60-92) 2 (5.7%) 0 87% (75-98)
Missing 47
EUTOS score
Low risk 238 (78%) 13 (5.5%) 93% (88-96) 3 (1.3%) 4 (1.7%) 98% (93-99)
High risk 68 (22%) 10 (14.7%) 81% (67-89) P=0.009 2 (3%) 3 (4.4%) 94% (83-99) P=0.340
Missing 44
EUTOS Long-Term Survival score
Low risk 199 (64%) 6 (3%) 96% (92-98) 1 (0.5%) 2 (1%) 99% (95-100)
Intermediate risk 68 (22%) 6 (8.8%) 88% (76-95) P<0.0001 2 (2.9%) 3 (4.4%) 96% (88-99) P=0.107
High risk 42 (14%) 11 (26.2%) 67% (49-82) 2 (4.8%) 2 (4.8%) 89% (70-98)
Missing 41
CI: confidence interval; CML: chronic myeloid leukemia; PFS: progression-free survival. Because of some lacking data (spleen size n=31; platelet count n=1; eosinophil count n
= 11; basophil count n=15 or blast and myeloblast percentage n=11) determination of at least one prognostic score was not possible in a total of 48 children (all scores and
EUTOS Long-Term Survival score were missing in 38 and 41 of them, respectively). All patients with critical events (progression and/or deaths) were assessable for the calculation
of the risk score.
years) and 56% were male; a palpable spleen was noted in
77% of the patients and the median spleen size was 5 cm
(range, 0 to 32 cm)  below the costal margin;  the median
white blood cell count and the median hemoglobin level
were 228x109/L (range, 4.8x109/L to 1037x109/L) and 94
g/L (range, 31 g/L to 170 g/L), respectively. 
The distribution of the children into the risk categories
by the Sokal (for patients less than 45 years), Euro, EUTOS
and ELTS scores is reported in Table 1. Discordant risk cat-
egorizations of the children were observed when compar-
ing the four scores. Regarding the Sokal (for patients less
than 45 years) and the ELTS scores, all the children catego-
rized as low risk according to the Sokal system were allo-
cated to the low-risk group according to the ELTS score.
By contrast, among the children in the intermediate-risk
group according to the Sokal system, only 13% remained
in the intermediate-risk group according to the ELTS score
while 1% and  86% were allocated to the high-risk group
and low-risk group,  respectively. Among the children in
the high-risk group according to the Sokal system, 30%
remained in the high-risk group according to the ELTS
score while 39% and 31% were allocated to the interme-
diate-risk group and low-risk group,  respectively. The
median follow up of the 350 patients in chronic phase
treated with imatinib front line was 3 years (range, 1
month to 6 years). Imatinib was administered with a
median observational time of 11 months (range, 1 to 131
months); 149 patients discontinued treatment with ima-
tinib because of progression of their disease, toxicity, fail-
ure to achieve optimal response, or physician’s choice
(HSCT in optimal response). Progression and/or death
(whichever came first) were recorded in 23 patients:  pro-
gression occurred in 19 (5.4%) patients and death was
recorded in 12 (3.4%) children. Among the 19 patients
who progressed as first event, five patients progressed to
accelerated phase and 14 to blastic phase at a median time
of 12 months (range, 3 to 32 months) after diagnosis.
Eleven of these 19 children are alive including ten who
were transplanted with a graft from a sibling donor (4
patients) or an unrelated donor (6 patients). The remaining
8/19 patients have died including  five children who died
of uncontrolled CML disease (2 children with recurrent
disease after HSCT  for disease progression of the disease)
and three who died after HSCT because of graft-versus-
host disease (n=1) or infection (n=2). In addition, death
occurred as the first event in four patients who were trans-
planted (unrelated donor 1 case, sibling donor 3 cases) in
first chronic phase in accordance with the choice of the
clinician. The causes of these four deaths were graft-ver-
sus-host disease (n=1) and infection (n=3). Overall, consid-
ering all 12 deaths, these occurred at a median time of 22
months (range, 12 to 56 months) after the diagnosis of
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Figure 1. Progression-free survival stratified according to risk categorization by the four scores. (A) Sokal score, (B) Euro score, (C) EUTOS score, (D) EUTOS Long-
Term Survival (ELTS) score. Green represent low risk patients, orange represent intermediate risk patients and red represents high-risk patients.
A
C D
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CML and five were related to CML while the other seven
deaths were due to post-transplant complications (graft-
versus-host disease 2 cases,  infection  5 cases) and for this
analysis were considered as non-CML-related deaths.
Overall, the 5-year overall survival rate was 94% (95%
CI: 90%-97%), the 5-year progression-free survival rate
was 92% (95% CI: 87%-94%) and the 5-year survival rate
accounting for competing events was 97% (95% CI: 94%-
99%). Among the patients allocated to the low-, interme-
diate- and high-risk groups by the ELTS score, events (pro-
gression and/or death) occurred in 6.0%, 8.8% and 26.2%,
respectively. When the patients were stratified according
to the Sokal, Euro, EUTOS and ELTS scores, only the
EUTOS and the ELTS scores were able to discriminate risk
groups with significantly different progression-free sur-
vival (P=0.009 and P<0.0001, respectively) (Table 1, Figure
1). None of the Sokal, Euro, EUTOS and ELTS scores was
able to discriminate risk groups with significant differ-
ences in survival based on CML deaths only (Table 1).
Discussion
The prognosis of adult patients with CML can be pre-
dicted with established prognostic scores based on clinical
(spleen size) and biological parameters. The characteristics
of CML differ with age with larger spleen size and higher
leukocyte count at diagnosis in the present population of
children and adolescents  than reported in adults with
CML.10-12 Because of the rarity of CML in children, a spe-
cific prognostic score incorporating clinical, biological and
molecular features has not been established for this popu-
lation. The Sokal and Euro scores were developed in a
cohort of patients including children with CML in the con-
ventional chemotherapy (busulfan, hydroxyurea) and in
the interferon eras, respectively.1,2 A Sokal score for young
patients was established in a cohort of patients less than
45 years old and is still useful in the era of therapy with
tyrosine kinase inhibitors.4,13 Subsequently, the EUTOS
scoring system was introduced in adult patients treated
with imatinib.3 The improved life expectancy of adults
with CML treated with imatinib currently approaches
that for the general population, with 41% to 44% of the
deaths not directly related to CML but rather to comor-
bidities.6,14,15 Based on the concept of competing risks, the
ELTS score was recently developed in order to consider
disease-specific death in adults with CML.6 This new
score differentiated the probability of dying of CML in the
adult population better than did the Sokal, Euro and
EUTOS scores.6 The aim of the present study was to test
the relevance of the ELTS score in a large cohort of chil-
dren and adolescents with CML. In the present cohort of
350 children treated with imatinib for CML in first chronic
phase, the ELTS score identified a lower proportion of
high-risk children than the Sokal score, as observed in
adults, while the proportions of the children allocated to
low-risk (64%), intermediate-risk (22%) and high-risk
(14%) groups by the ELTS score  were similar to the pro-
portions reported in adults.6
The 5-year progression-free survival rate of 92% for the
entire cohort of children is consistent with previous
reports in children and adults with CML in chronic phase
treated with imatinib front line.16-19 The recently developed
ELTS score divided the children of the present study into
three separate risk groups according to their progression-
free survival with all risk groups differing significantly
from each other. The ELTS score showed better differen-
tiation of progression-free survival than the other scores in
our cohort of children and could be used to predict the
long-term outcome of children with CML in chronic
phase. This finding suggests the establishment of new
treatment policies with the incorporation of this score into
the therapeutic algorithms of the current recommenda-
tions proposed for childhood CML.20 The high probability
of progression for children allocated to the high-risk group
could favor risk-adapted treatment with the use of sec-
ond-generation tyrosine kinase inhibitors as first-line ther-
apy in these patients.
The estimated 5-year overall survival rate reported in
our non-selected cohort of children compares favorably
with results reported in adults treated in trials with ima-
tinib.21,22 Although children have more aggressive features
at presentation compared to adults,  probabilities of over-
all survival remain high and comparable in children, in
adolescents and in young adults treated with imatinib.10,11,23
Because the improvement in the survival of patients with
CML after introduction of imatinib has resulted in
increased life expectancy, about half of adult patients now
die of causes unrelated of CML. The main non-related
CML deaths reported in adults in the tyrosine kinase
inhibitor era are those due to secondary malignancies and
cardiovascular events.6,24 Thus CML-related death could
represent a better assessment of treatment efficacy. In the
present study, the 5-year survival rate accounting for com-
peting events of 97% corresponded to a 3% probability of
death because of CML which is rather similar to the 4%
probability reported in adults.6 However, in contrast to the
adult study, the follow up was not censored at transplan-
tation in the present study, consequently deaths from
HSCT are competing events. The non-related CML deaths
notified in the present study were due to post-transplant
complications and were more common than CML as a
cause of death. Thus  HSCT should be reserved for cases
of treatment failure in children in chronic phase, as pro-
posed in the recommendation of the International Berlin-
Frankfurt-Munster study group.20
The ELTS score discriminates the probability of dying of
CML better than do the Sokal, Euro and EUTOS scores in
adults with CML. In the present study none of these
scores was able to discriminate risk groups with signifi-
cant differences in survival based on CML deaths only
.The low number of events (only 5 CML-related deaths) is
one of the possible explanations for these findings.
Moreover, because of the low number of comorbidities in
the pediatric population, the risk of dying due to compet-
ing events is restricted to the complications of HSCT.
In this pediatric cohort, the ELTS score demonstrated
better differentiation of progression-free survival than did
the Sokal (in patients less than 45 years old) and Euro
scores in children and adolescents with CML in chronic
phase treated with imatinib. We therefore propose that
the ELTS score should be considered in therapeutic algo-
rithms and clinical trials in children and adolescents.
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